Oh Chan Kwon, Jang Woo Ha, Yong-Beom Park, Sang-Won Lee
{"title":"Incorporation of patient-reported outcomes in the clinical risk score to improve relapse prediction in ANCA-associated vasculitis.","authors":"Oh Chan Kwon, Jang Woo Ha, Yong-Beom Park, Sang-Won Lee","doi":"10.55563/clinexprheumatol/l2mg3x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate whether integration of patient-reported outcomes (PROs), particularly the 36-item short form health survey (SF-36), with the French Vasculitis Study Group relapse score (FRS) improves relapse prediction in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA).</p><p><strong>Methods: </strong>This retrospective cohort study included 98 patients with MPA or GPA whose baseline and first-year follow-up SF-36 data were available. The predictive accuracy of the FRS, baseline SF-36 physical component summary (PCS) and mental component summary (MCS), and first-year cumulative SF-36 PCS and MCS for relapse was evaluated using receiver operating characteristic curve analysis. The area under the curve (AUC) with 95% confidence interval (CI) was estimated for each variable. A combination of FRS and PRO with higher accuracy was developed using multivariable Cox regression incorporating variables significantly associated with relapse.</p><p><strong>Results: </strong>During a median follow-up of 50.9 months, 28 patients (28.6%) experienced relapse. The FRS (AUC=0.666, 95% CI=0.552-0.780, p=0.010) and first-year cumulative SF-36 PCS (AUC=0.629, 95% CI=0.503-0.755, p=0.047) significantly predicted relapse, whereas baseline SF-36 PCS and MCS and first-year cumulative SF-36 MCS did not. A combination of the FRS and first-year cumulative SF-36 PCS demonstrated improved predictive performance (AUC=0.727, 95% CI=0.623-0.830, p<0.001).</p><p><strong>Conclusions: </strong>The first-year cumulative SF-36 PCS was independently associated with relapse in patients with MPA or GPA, and its integration with the FRS improved relapse risk prediction. These findings support a multidimensional approach incorporating both clinical and patient-reported data to better stratify relapse risk and inform treatment planning in MPA or GPA.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/l2mg3x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To evaluate whether integration of patient-reported outcomes (PROs), particularly the 36-item short form health survey (SF-36), with the French Vasculitis Study Group relapse score (FRS) improves relapse prediction in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA).
Methods: This retrospective cohort study included 98 patients with MPA or GPA whose baseline and first-year follow-up SF-36 data were available. The predictive accuracy of the FRS, baseline SF-36 physical component summary (PCS) and mental component summary (MCS), and first-year cumulative SF-36 PCS and MCS for relapse was evaluated using receiver operating characteristic curve analysis. The area under the curve (AUC) with 95% confidence interval (CI) was estimated for each variable. A combination of FRS and PRO with higher accuracy was developed using multivariable Cox regression incorporating variables significantly associated with relapse.
Results: During a median follow-up of 50.9 months, 28 patients (28.6%) experienced relapse. The FRS (AUC=0.666, 95% CI=0.552-0.780, p=0.010) and first-year cumulative SF-36 PCS (AUC=0.629, 95% CI=0.503-0.755, p=0.047) significantly predicted relapse, whereas baseline SF-36 PCS and MCS and first-year cumulative SF-36 MCS did not. A combination of the FRS and first-year cumulative SF-36 PCS demonstrated improved predictive performance (AUC=0.727, 95% CI=0.623-0.830, p<0.001).
Conclusions: The first-year cumulative SF-36 PCS was independently associated with relapse in patients with MPA or GPA, and its integration with the FRS improved relapse risk prediction. These findings support a multidimensional approach incorporating both clinical and patient-reported data to better stratify relapse risk and inform treatment planning in MPA or GPA.
期刊介绍:
Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.